Total
0
Shares
Orthocell (ASX:OCC) - CEO, Paul Anderson (left)
CEO, Paul Anderson (left)
Source: Orthocell
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Regenerative medicine company Orthocell (OCC) secures Chinese and New Zealand patents for its novel CelGro collagen medical device 
  • The patents, titled “Sutureless repair of soft tissue”, are now approved in Australia, New Zealand, China and Japan, with further applications progressing in US and Europe
  • The patents are set to expire on 12 October 2035
  • Orthocell was up 1.77 per cent, trading at 57.5 cents per share at 11:45 am AEST

Regenerative medicine company Orthocell (OCC) has secured Chinese and New Zealand patents for its novel CelGro collagen medical device for soft tissue regeneration.

The patents, titled “Sutureless repair of soft tissue,” are now approved in Australia, New Zealand, China and Japan, with further applications progressing in US and Europe.

Sutureless repair of soft tissue means repairing damaged soft tissue without the use of damaging stitches.

Orthocell said sutureless repair had the potential to greatly improve the efficiency of surgical procedures by simplifying techniques, reducing surgery time and reducing the risk of additional trauma to soft tissue caused by the use of stitches.

Orthocell’s patented method of sutureless repair involves the use of CelGro, the company’s resorbable collagen medical device. CelGro acts as a cell scaffold when implanted at the site of tissue injury, encouraging new cell growth. Cells from the regenerating tissue integrate with the collagen fibres to guide tissue regeneration.

“These patents are an important addition to our global intellectual property portfolio, further strengthening our position in regenerative medicine product development and novel surgical techniques for soft tissue repair,” Orthocell Managing Director Paul Anderson said.

“This comes at a perfect time for the company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process in the US, European Union and Australia.”

The patents are set to expire on 12 October 2035.

Orthocell was up 1.77 per cent, trading at 57.5 cents per share at 11:45 am AEST.


OCC by the numbers
More From The Market Herald
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.